177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the dose and schedule of 177Lu-PSMA-617 and pembrolizumab in
treating patients with castration-resistant prostate cancer that has spread to other places
in the body. 177Lu-PSMA-617 carries a radioactive component which attached to the prostate
specific membrane antigen (PSMA) receptor found on tumor cells. Its radiation component
destroys the tumor cell. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may
help the body?s immune system attack the cancer, and may interfere with the ability of tumor
cells to grow and spread. Giving 177Lu-PSMA-617 and pembrolizumab may work better at treating
prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
National Cancer Institute (NCI) Prostate Cancer Foundation